Admitted Students

There are very few people in the world who can claim to turn missiles into medicine but John Zehner (BS ’91) is among them.

Zehner, a nuclear pharmacist, is partner and CEO of SpectronRx, a contract manufacturing and development organization that specializes in radiopharmaceuticals. In 2027, when Purdue’s new Nursing and Pharmacy Education Building opens, the nuclear pharmacy lab will be outfitted with state-of-the-art equipment because of Zehner’s generosity on Purdue Day of Giving.

The FOE—Friends of Emily, for those not yet in the know—refer to Dr. Emily Hancock (PharmD ’92) as the EOF: Epicurean of Fun.

It’s a title she happily embraces, but it’s also a title that’s far from telling the whole story of who she is. Emily, the widow of former Purdue University College of Pharmacy Professor Bruce Hancock (BS ’75, MS ’77), says she grew up with a mother who could make even the most mundane tasks feel like a good time—a perspective Emily has held tight to even in the depths of unimaginable adversity.

Purdue researchers develop fully off-the-shelf, stem cell-derived, natural killer cells against glioblastoma

WEST LAFAYETTE, Ind. — Purdue University researchers are developing and validating a patent-pending treatment for incurable glioblastoma brain tumors. Glioblastomas are almost always lethal with a median survival time of 14 months. Traditional methods used against other cancers, like chemotherapy and immunotherapy, are often ineffective on glioblastoma.